What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer?

被引：1

作者：

Lewis, Matthieu ^{[1
]}

Copland, Mhairi ^{[2
]}

Soverini, Simona ^{[3
]}

Sadovnik, Irina ^{[4
]}

Bedel, Aurelie ^{[5
]}

Prost, Stephane ^{[7
]}

Italiano, Antoine ^{[6
]}

Mahon, Francois-Xavier ^{[1
]}

机构：

[1] Univ Bordeaux, Lab Mammary & Leukem Oncogenesis Genet Div & Resi, ACTION, INSERM,U1218, Bordeaux, Gironde, France

[2] Univ Glasgow, Inst Canc Sci, Glasgow City Counsil, Glasgow, Lanark, Scotland

[3] Univ Bologna, Dept Expt Diagnost & Specialty Med, Haematol Oncol L & A Seragnoli, Bologna, Emilia Romagna, Italy

[4] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med 1, Vienna, Austria

[5] Univ Bordeaux, Biotherapie Malad Genet & Canc, INSERM, U1035, Bordeaux, Gironde, France

[6] Bergonie Inst, Dept Med Oncol, Bordeaux, Gironde, France

[7] CEA, Inst Emerging Dis & Innovat Therapies IMETI, F-92265 Fontenay Aux Roses, Ile De France, France

来源：

HEMATOLOGICAL ONCOLOGY | 2017年 / 35卷 / 04期

关键词：

chronic myeloid leukemia; tyrosine kinase inhibitors; resistance to treatment; leukemic stem cells; ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN-CELLS; STEM-CELLS; IMATINIB; DASATINIB; THERAPY; MUTATIONS; PONATINIB; CML; DISCONTINUATION;

D O I：

10.1002/hon.2329

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the past decade, the treatment of chronic myeloid leukemia (CML) has undergone a drastic evolution. The discovery and success of imatinib and second-generation tyrosine kinase inhibitors have substantially increased the outcome for CML patients. The next step in medical and scientific research is to better understand the malignancy so as to eventually find a cure to eliminate all leukemic cells from patients. One of the key issues is about the resistance of the leukemic stem cells to tyrosine kinase inhibitors. Here, we briefly describe our current studies on CML resistance, and leukemic stem cell modeling and characterization.

引用

页码：420 / 423

页数：4

共 30 条

[1]

[Anonymous], J AM ACAD DERMATOL

[2] Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents [J].

Cai, Jin ;

Sun, Min ;

Wu, Xiaoqing ;

Chen, Junqing ;

Wang, Peng ;

Zong, Xi ;

Ji, Min .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 63 :702-712

[3] Recent progress on third generation covalent EGFR inhibitors [J].

Cheng, Hengmiao ;

Nair, Sajiv K. ;

Murray, Brion W. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (08) :1861-1868

[4]

Chomel JC, 2011, ONCOTARGET, V2, P713

[5] Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia [J].

Cortes, Jorge ;

Hochhaus, Andreas ;

Hughes, Timothy ;

Kantarjian, Hagop .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (05) :524-531

[6] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J].

Druker, Brian J. ;

Guilhot, Francois ;

O'Brien, Stephen G. ;

Gathmann, Insa ;

Kantarjian, Hagop ;

Gattermann, Norbert ;

Deininger, Michael W. N. ;

Silver, Richard T. ;

Goldman, John M. ;

Stone, Richard M. ;

Cervantes, Francisco ;

Hochhaus, Andreas ;

Powell, Bayard L. ;

Gabrilove, Janice L. ;

Rousselot, Philippe ;

Reiffers, Josy ;

Cornelissen, Jan J. ;

Hughes, Timothy ;

Agis, Hermine ;

Fischer, Thomas ;

Verhoef, Gregor ;

Shepherd, John ;

Saglio, Giuseppe ;

Gratwohl, Alois ;

Nielsen, Johan L. ;

Radich, Jerald P. ;

Simonsson, Bengt ;

Taylor, Kerry ;

Baccarani, Michele ;

So, Charlene ;

Letvak, Laurie ;

Larson, Richard A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2408-2417

[7] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].

Gorre, ME ;

Mohammed, M ;

Ellwood, K ;

Hsu, N ;

Paquette, R ;

Rao, PN ;

Sawyers, CL .

SCIENCE, 2001, 293 (5531) :876-880

[8] Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy [J].

Hochhaus, Andreas ;

Kantarjian, Hagop M. ;

Baccarani, Michele ;

Lipton, Jeffrey H. ;

Apperley, Jane F. ;

Druker, Brian J. ;

Facon, Thierry ;

Goldberg, Stuart L. ;

Cervantes, Francisco ;

Niederwieser, Dietger ;

Silver, Richard T. ;

Stone, Richard M. ;

Hughes, Timothy P. ;

Muller, Martin C. ;

Ezzeddine, Rana ;

Countouriotis, Athena M. ;

Shah, Neil P. .

BLOOD, 2007, 109 (06) :2303-2309

[9] Ponatinib: A Review of Its Use in Adults with Chronic Myeloid Leukaemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia [J].

Hoy, Sheridan M. .

DRUGS, 2014, 74 (07) :793-806

[10] shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance [J].

Khorashad, Jamshid S. ;

Eiring, Anna M. ;

Mason, Clinton C. ;

Gantz, Kevin C. ;

Bowler, Amber D. ;

Redwine, Hannah M. ;

Yu, Fan ;

Kraft, Ira L. ;

Pomicter, Anthony D. ;

Reynolds, Kimberly R. ;

Iovino, Anthony J. ;

Zabriskie, Matthew S. ;

Heaton, William L. ;

Tantravahi, Srinivas K. ;

Kauffman, Michael ;

Shacham, Sharon ;

Chenchik, Alex ;

Bonneau, Kyle ;

Ullman, Katharine S. ;

O'Hare, Thomas ;

Deininger, Michael W. .

BLOOD, 2015, 125 (11) :1772-1781

← 1 2 3 →